Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)
  4. Volume 22, Issue 4
  5. Article
Volume 22, Issue 4
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Background and Objectives

Hypercholesterolemia is one of the main risk factors for vascular thrombosis in individuals. Therefore, the use of statins is very effective in reducing cholesterol and can reduce the risk of thrombosis in these patients. Rosuvastatin, a member of the statin family which, inhibits cholesterol synthesis. Very few studies have been done in relation to how rosuvastatin can affect thrombosis. So, this research has been tried whether rosuvastatin can have an effect on coagulation factors and homocysteine as risk factors for thrombosis in hypercholesterolemia?

Methods

In this experimental study, 60 patients (30 men and 30 women with a mean age of 40-70 years) diagnosed with hypercholesterolemia (cholesterol > 250 mg/dl) participated in this research. 30 patients were prescribed rosuvastatin (20 mg/day), and 30 patients were simultaneously taken placebo for three months. All parameters, including FVIII, FV, Fibrinogen, D-Dimer, plasma homocysteine level and lipid profile, were measured before and after treatment. All the results were statistically compared between the two groups.

Results

In patients who took rosuvastatin, the drug was able to significantly reduce the concentrations of total cholesterol, triglycerides, and low-density lipoprotein (LDL) ( < 0.001). Also, rosuvastatin was able to reduce the concentrations of homocysteine significantly, D-Dimer ( < 0.001), coagulation factor VIII and factor V ( < 0.05). In patients with hypercholesterolemia who took the placebo, did not affect the mentioned variables ( > 0.05).

Conclusion

According to the results, it seems that rosuvastatin may be able to reduce the risk of thrombosis in patients by affecting coagulation factors and homocysteine levels.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/0118715257279903231205110750
2024-12-01
2024-11-22

  • From This Site

    /content/journals/chamc/10.2174/0118715257279903231205110750
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CarvalhoA.C.A. ColmanR.W. LeesR.S. Platelet function in hyperlipoproteinemia.N. Engl. J. Med.1974290843443810.1056/NEJM197402212900805 4359434
     [Google Scholar]
  2. AviramM. BrookG.J. The effect of human plasma on platelet function in familial hypercholesterolemia.Thromb. Res.198226210110910.1016/0049‑3848(82)90019‑6 7112508
     [Google Scholar]
  3. PrasadK. MishraM. Mechanism of hypercholesterolemia-induced atherosclerosis.Rev. Cardiovasc. Med.202223621210.31083/j.rcm2306212
     [Google Scholar]
  4. SugrueD.D. TraynerI. ThompsonG.R. VereV.J. DimesonJ. StirlingY. MeadeT.W. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia.Heart198553326526810.1136/hrt.53.3.265 3970784
     [Google Scholar]
  5. IcliA. AksoyF. NarG. KaymazH. AlpayM.F. NarR. GucluA. ArslanA. DoganA. Increased mean platelet volume in familial hypercholesterolemia.Angiology201667214615010.1177/0003319715579781 25859052
     [Google Scholar]
  6. BoosC.J. LipG.Y.H. Assessment of mean platelet volume in coronary artery disease-what does it mean?Thromb. Res.20071201111310.1016/j.thromres.2006.09.002 17046049
     [Google Scholar]
  7. MartinelliN. GirelliD. LunghiB. PinottiM. MarchettiG. MalerbaG. PignattiP.F. CorrocherR. OlivieriO. BernardiF. Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile.Blood2010116255688569710.1182/blood‑2010‑03‑277079 20810930
     [Google Scholar]
  8. FaehD. ChioleroA. PaccaudF. Homocysteine as a risk factor for cardiovascular disease: Should we (still) worry about?Swiss Med. Wkly.200613647-48745756 17225194
     [Google Scholar]
  9. ChaturvedulaR. RaoK. RampureD. RaoD. BhaskarM. Atherogenic activity of hypercholesterolemia and hyperhomocysteinemia in complicated type 2 diabetes mellitus.IJHSR2014446168
     [Google Scholar]
  10. FowlerB. Homocystein--an independent risk factor for cardiovascular and thrombotic diseases.Ther. Umsch.200562964164610.1024/0040‑5930.62.9.641 16218503
     [Google Scholar]
  11. DeyhimM.R. KhoshnaghshF. Plasma homocysteine level and risk of thrombosis.J. Appl. Environ. Biol. Sci.2016621789193
     [Google Scholar]
  12. WilsonK.M. McCawR.B. LeoL. ArmingE. LhotokS. TtglieriB. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice.Arterioscler. Thromb. Vasc. Biol.2007271233240
     [Google Scholar]
  13. ZamaniA. OmraniG.R. LankaraniK.B. Hyperhomocysteinaemia, hyperlipidaemia and risk of venous thromboembolism in Shiraz.East. Mediterr. Health J.200395-693594310.26719/2003.9.5‑6.935 16450523
     [Google Scholar]
  14. KocherG. HimmelmannA. Portal vein thrombosis (PVT): A study of 20 non-cirrhotic cases.Swiss Med. Wkly.200513525-2637237610.4414/smw.2005.11035 16106327
     [Google Scholar]
  15. Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials.Lancet20193931017040741510.1016/S0140‑6736(18)31942‑1 30712900
     [Google Scholar]
  16. SoranH. AdamS. DurringtonP.N. Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat.Eur. J. Prev. Cardiol.2017241768310.1177/2047487316667785 27609614
     [Google Scholar]
  17. San NorbertoE.M. GastambideM.V. TaylorJ.H. García-SaizI. VaqueroC. Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis.Vasa201645213314010.1024/0301‑1526/a000507 27058799
     [Google Scholar]
  18. NguyenC.D. AnderssonC. JensenT.B. GjesingA. Schjerning OlsenA.M. Malta HansenC. BüllerH. Torp-PedersenC. GislasonG.H. Statin treatment and risk of recurrent venous thromboembolism: A nationwide cohort study.BMJ Open2013311e00313510.1136/bmjopen‑2013‑003135 24202053
     [Google Scholar]
  19. BiedermannJ.S. KruipM.J.H.A. van der MeerF.J. RosendaalF.R. LeebeekF.W.G. CannegieterS.C. LijferingW.M. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis.Eur. Heart J.201839191740174710.1093/eurheartj/ehy014 29394348
     [Google Scholar]
  20. LeiC. HauL.I. QiangX. YiJ. The effect of atorvastatin on homocysteine and carotid artery atherosclerosis in patient with H type hypertension.Chinese J. Arteriosclerosis.2015238817820
     [Google Scholar]
  21. AkbariA. IslampanahM. ArhaminiyaH. Alvandi FardM.M. JamialahmadiT. SahebkarA.H. Impact of statin or fibrate therapy on homocysteine concentration: A systematic review and mata-analysis.Curr. Med. Chem.2023311419201940
     [Google Scholar]
  22. ZinelluA. MangoniA.A. Effect of statin treatment on homocysteine concentrations: An updated systematic review and meta-analysis with meta-regression.Expert Rev. Clin. Pharmacol.202215444345910.1080/17512433.2022.2072293 35482022
     [Google Scholar]
  23. GengJ. XuH. FuW. YuX. XuG. CaoH. LinG. SuiD. Rosuvastatin protects against endothelial cell apoptosis in vitro and alleviates atherosclerosis in ApoE/mice by suppressing endoplasmic reticulum stress.Exp. Ther. Med.202020155056010.3892/etm.2020.8733 32537013
     [Google Scholar]
  24. DennisW. RobertH. KnoppM.D. A comparative effect of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.Am. J. Cardiol.2003911334110.1016/S0002‑9149(02)02994‑6 12505568
     [Google Scholar]
  25. GuttormsenA.B. SchneedeJ. FiskerstrandT. UelandP.M. RefsumH.M. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects.J. Nutr.1994124101934194110.1093/jn/124.10.1934 7931702
     [Google Scholar]
  26. LüftjohannD. SigitJ.I. LocatelliS. von BergmannK. SchmidtH.H.A. High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesterolemia.Atherosclerosis2001155126526610.1016/S0021‑9150(00)00735‑8 11293393
     [Google Scholar]
  27. RidkerP.M. ShihJ. CookT.J. ClearfieldM. DownsJ.R. PradhanA.D. WeisS.E. GottoA.M. Jr Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.Circulation2002105151776177910.1161/01.CIR.0000014447.06099.FB 11956118
     [Google Scholar]
  28. BaoX.M. WuC.F. LuG.P. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK.Atherosclerosis2010210111412110.1016/j.atherosclerosis.2009.11.032 20018284
     [Google Scholar]
  29. BaoX. WuC. LuG. Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling.Acta Pharmacol. Sin.200930101392139810.1038/aps.2009.135 19767766
     [Google Scholar]
  30. GhanimaW. AbdelnoorM. MowinckelM.C. SandsetP.M. The performance of STA‐Liatest D ‐dimer assay in out‐patients with suspected pulmonary embolism.Br. J. Haematol.2006132221021510.1111/j.1365‑2141.2005.05859.x 16398655
     [Google Scholar]
  31. RavnskovU. de LorgerilM. KendrickM. DiamondD.M. Importance of coagulation factors as critical components of premature cardiovascular disease in familial hypercholesterolemia.Int. J. Mol. Sci.20222316914610.3390/ijms23169146 36012410
     [Google Scholar]
  32. AlirezaeiT. IrilouzadianR. IrilouzadianR. Response: Comment on “Significant decrease in plasma D‐dimer levels and mean platelet volume after a 3‐month treatment with rosuvastatin in patients with venous thromboembolism”.Clin. Cardiol.2022451097610.1002/clc.23916 36073528
     [Google Scholar]
  33. BordbarM. de MutsertR. CevvalM. RosendaalF.R. JukemaJ.W. LijferingW.M. LijferingW.M. Differential effect of statin use on coagulation markers: An active comparative analysis in the NEO study.Thromb. J.20211914510.1186/s12959‑021‑00299‑2 34176487
     [Google Scholar]
  34. TripodiA. PellegattaF. ChantarangkulV. GrigoreL. GarlaschelliK. BaragettiA. LemmaL. CatapanoA. Statins decrease thrombin generation in patients with hypercholesterolemia.Eur. J. Intern. Med.201425544945110.1016/j.ejim.2014.03.016 24784951
     [Google Scholar]
  35. UndasA. Brummel-ZiedinsK.E. MannK.G. Statins and blood coagulation.Arterioscler. Thromb. Vasc. Biol.200525228729410.1161/01.ATV.0000151647.14923.ec 15569822
     [Google Scholar]
  36. WoestijneA. GraafY. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.J. Am. Coll. Cardiol.2013622018341841
     [Google Scholar]
  37. RidkerP.M. DanielsonE. FonsecaF.A.H. GenestJ. GottoA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N. Engl. J. Med.20083592121952207
     [Google Scholar]
/content/journals/chamc/10.2174/0118715257279903231205110750
Loading
Can Rosuvastatin Reduce the Risk of Thrombosis in Patients with Hypercholesterolemia with its Effect on Coagulation Factors and Homocysteine Levels?
Cardiovasc. Hematol. Agents Med. Chem. 22, 495 (2024); https://doi.org/10.2174/0118715257279903231205110750
/content/journals/chamc/10.2174/0118715257279903231205110750
/content/journals/chamc/10.2174/0118715257279903231205110750
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): coagulation; homocysteine; Hypercholesterolemia; lipid profile; rosuvastatin; thrombosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test